Wexford Capital LP Biotechnology

Wexford Capital LP

$310 Million
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
CRSP Crispr Therapeutics Ag	$4.19B	$433,000 0.14% of portfolio	8,906	Q2 2025 New
TGTX Tg Therapeutics, Inc.	$4.7B	$431,000 0.14% of portfolio	12,000	Q2 2025 Added 20.0%
ARGX Argenx Se	$42.5B	$275,000 0.09% of portfolio	500	Q2 2025 Reduced 66.67%
BEAM Beam Therapeutics Inc.	$1.43B	$245,000 0.08% of portfolio	14,453	Q2 2025 New
LRMR Larimar Therapeutics, Inc.	$166M	$201,000 0.06% of portfolio	69,799	Q2 2025 New
IONS Ionis Pharmaceuticals Inc	$8.66B	$187,000 0.06% of portfolio	4,749	Q2 2025 New
PTGX Protagonist Therapeutics, Inc	$2.76B	$183,000 0.06% of portfolio	3,315	Q2 2025 New
RZLT Rezolute, Inc.	$317M	$171,000 0.06% of portfolio	38,348	Q2 2025 New
CYTK Cytokinetics Inc	$4.9B	$168,000 0.05% of portfolio	5,107	Q2 2025 New
ARQT Arcutis Biotherapeutics, Inc.	$1.04B	$162,000 0.05% of portfolio	11,558	Q2 2025 New
VERA Vera Therapeutics, Inc.	$669M	$161,000 0.05% of portfolio	6,864	Q2 2025 Reduced 83.77%
ACLX Arcellx, Inc.	$3.16B	$159,000 0.05% of portfolio	2,420	Q2 2025 Reduced 81.1%
NUVB Nuvation Bio Inc.	$758M	$159,000 0.05% of portfolio	81,590	Q2 2025 Reduced 89.44%
APLS Apellis Pharmaceuticals, Inc.	$2.96B	$158,000 0.05% of portfolio	9,139	Q2 2025 New
SLN Silence Therapeutics PLC	$193M	$157,000 0.05% of portfolio	27,149	Q2 2025 New
JANX Janux Therapeutics, Inc.	$1.03B	$151,000 0.05% of portfolio	6,541	Q2 2025 New
ARWR Arrowhead Pharmaceuticals, Inc.	$2.88B	$145,000 0.05% of portfolio	9,229	Q2 2025 New
CGEM Cullinan Oncology, Inc.	$312M	$141,000 0.05% of portfolio	18,726	Q2 2025 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	382,555	Q2 2025 Reduced 6.36%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Wexford Capital LP with notifications on news.